1. Pink Sheet

Medicare Drug Price Inflation Rebate Invoice Distribution Will Start In 2025, CMS Says

 
• By Cathy Kelly

Coinsurance for Part B drugs may reflect rebates by April, and sponsors are already liable for them, but payments will be delayed several years as CMS develops its systems. Agency seeks comment on how to account for 340B discounts and make allowances for drug shortages, among other issues.

CMS Using Timing Flexibility Allowed By Law In Implementing Rebate Program • Source: Shutterstock

The Centers for Medicare and Medicaid Services will not begin sending out invoices for price inflation rebates owed by manufacturers on Parts B and D drugs until 2025 even though rebate liability has already begun, according to the agency.

The delay in releasing invoices is allowed by the Inflation Reduction Act, which established the rebate program, and will give CMS time to set up the appropriate systems for managing the program, deputy administrator and Center for

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

House Budget Bill Includes Delayed Orphan Fix, Also Risks Downstream Cell and Gene Coverage

 
• By Sarah Karlin-Smith

The first two classes of negotiated drugs under the Inflation Reduction Act would not benefit from a rare disease adjustment House Republicans included in their reconciliation package.

Trump’s Rx Pricing Order: The Best-Case And Worst-Case Scenarios

 
• By Derrick Gingery

US trade and tariff leverage might successfully push European and other countries to pay more for medicines, but if not, President Trump’s executive order includes potential US drug withdrawal and other options to entice industry to lower US prices.

International Group Aims To Shape The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.